Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Nov 16, 2022

Keywords

ClinConnect Summary

This clinical trial, titled "Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets," is studying the best treatment options for patients who have both venous thromboembolism (VTE) and heart or blood vessel diseases. VTE includes conditions like deep vein thrombosis (DVT) and pulmonary embolism (PE), which can happen when blood clots form and block blood flow. The trial is looking at how well different combinations of blood-thinning medications can prevent further complications while managing the risks of side effects, like bleeding.

To participate in this trial, individuals need to be between the ages of 65 and 74, have a confirmed diagnosis of a recent DVT or PE, and be prescribed specific medications to prevent further heart and blood vessel issues. They also need to be able to provide informed consent and expect to live for more than three months. Participants can expect to receive careful monitoring and support throughout the study. It's important to know that the trial is currently recruiting, so there is an opportunity for eligible patients to contribute to important research that could improve treatment for others in the future.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • Signed informed consent
• • Patients with acute objectively confirmed symptomatic proximal deep-vein thrombosis (DVT) or pulmonary embolism (PE) (with or without deep-vein thrombosis). Proximal deep-vein thrombosis is defined as thrombosis involving at least the popliteal vein or a more proximal vein of the lower limb.
• • Indication of full-dose anticoagulant therapy for at least 3 months.
• • Prescription of antiplatelet therapy for secondary prevention of atherosclerotic cardiovascular diseases, at the time of VTE diagnosis
• • Life expectancy more than 3 months
• • Social security affiliation
• Exclusion Criteria:
• • Unable to give informed consent
• • Active bleeding or a high risk of bleeding contraindicating anticoagulant treatment; a systolic blood pressure of more than 180 mm Hg or a diastolic blood pressure of more than 110 mm Hg
• • Anticoagulation for more than 5 days prior to randomization
• • Active pregnancy or expected pregnancy or no effective contraception
• • Isolated distal deep vein thrombosis
• • Antiplatelet therapy prescribed for primary prevention of cardiovascular disease
• • Indication to maintain a dual-antiplatelet therapy.
• • Triple positive antiphospholipid syndrome, with arterial thrombosis
• • Major cardiovascular and cerebrovascular event in the past 12 months for acute coronary syndrome, and in the past 6 months for cerebrovascular diseases and peripheral arterial diseases